Marc Scherlinger

Marc Scherlinger

Strasbourg, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 77 publications

Comment on: Acute myocarditis after switching between two adalimumab biosimilars: reply.

Comment on: Acute myocarditis after switching between two adalimumab biosimilars: reply.

Journal: Rheumatology (Oxford, England)

Published: July 29, 2026

Suspected ICANS in systemic sclerosis: think twice before corticosteroids.

Suspected ICANS in systemic sclerosis: think twice before corticosteroids.

Journal: Rheumatology (Oxford, England)

Published: June 15, 2026

Immune reset after deep B-lineage depletion: remission is not reprogramming.

Immune reset after deep B-lineage depletion: remission is not reprogramming.

Journal: Annals of the rheumatic diseases

Published: May 25, 2026

Low-dose and very low-dose glucocorticoids: which low is low risk?

Low-dose and very low-dose glucocorticoids: which low is low risk?

Journal: The Lancet. Rheumatology

Published: April 27, 2026

The why, what, who and when of B cell depletion in systemic lupus erythematosus: biological rationale, patient stratification and evolving therapeutic modalities.

The why, what, who and when of B cell depletion in systemic lupus erythematosus: biological rationale, patient stratification and evolving therapeutic modalities.

Journal: Rheumatology (Oxford, England)

Published: March 19, 2026

Relapse risk of lupus-related serositis according to immunosuppressive therapy: a national real-world study.

Relapse risk of lupus-related serositis according to immunosuppressive therapy: a national real-world study.

Journal: RMD open

Published: March 09, 2026

Acute myocarditis after switching between two adalimumab biosimilars.

Acute myocarditis after switching between two adalimumab biosimilars.

Journal: Rheumatology (Oxford, England)

Published: February 09, 2026

Reprogramming CAR T cells across genetic, epigenetic, metabolic and microenvironmental axes to improve efficacy and safety in cancer and autoimmune disease.

Reprogramming CAR T cells across genetic, epigenetic, metabolic and microenvironmental axes to improve efficacy and safety in cancer and autoimmune disease.

Journal: Frontiers in immunology

Published: February 07, 2026

Safety and efficacy of blinatumomab in the treatment of refractory systemic sclerosis: a case series.

Safety and efficacy of blinatumomab in the treatment of refractory systemic sclerosis: a case series.

Journal: Annals of the rheumatic diseases

Published: December 18, 2025

Systemic lupus pregnancies are characterized by an intrinsic pro-inflammatory monocyte transcriptome, driven by an aberrant miRNA signature.

Systemic lupus pregnancies are characterized by an intrinsic pro-inflammatory monocyte transcriptome, driven by an aberrant miRNA signature.

Journal: Journal of translational autoimmunity

Published: December 03, 2025

Carbon Footprint of Antibody-Based Drugs and Biologics Using Hybrid Life Cycle Assessment.

Carbon Footprint of Antibody-Based Drugs and Biologics Using Hybrid Life Cycle Assessment.

Journal: Clinical pharmacology and therapeutics

Published: November 20, 2025

Roads and detours for CAR T cell therapy in autoimmune diseases.

Roads and detours for CAR T cell therapy in autoimmune diseases.

Journal: Nature reviews. Drug discovery

Published: November 18, 2025

Showing 1-12 of 77

Last Updated: 09/26/2026